Taiwan Biomaterial Co., Ltd. (TPEX:6649)
49.35
+0.05 (0.10%)
Jan 22, 2026, 1:30 PM CST
Taiwan Biomaterial Revenue
Taiwan Biomaterial had revenue of 72.78M TWD in the quarter ending September 30, 2025, with 164.73% growth. This brings the company's revenue in the last twelve months to 203.27M, up 142.73% year-over-year. In the year 2024, Taiwan Biomaterial had annual revenue of 96.57M with 32.59% growth.
Revenue (ttm)
203.27M
Revenue Growth
+142.73%
P/S Ratio
10.20
Revenue / Employee
5.81M
Employees
35
Market Cap
2.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96.57M | 23.74M | 32.59% |
| Dec 31, 2023 | 72.84M | -54.47M | -42.79% |
| Dec 31, 2022 | 127.31M | 85.63M | 205.48% |
| Dec 31, 2021 | 41.67M | 23.60M | 130.56% |
| Dec 31, 2020 | 18.08M | 1.53M | 9.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |
| Caliway Biopharmaceuticals | 34.99M |